[Myelodysplastic neoplasms with acute myeloid leukemia-like mutations: clinical features, molecular profiles, and prognosis]. [PDF]
Bao ZF +13 more
europepmc +1 more source
[Efficacy of ruxolitinib and prognostic factors in patients with myelofibrosis stratified by age]. [PDF]
Liu XH +10 more
europepmc +1 more source
[Research progress on targeted delivery of proteasome inhibitor nanoparticles for the treatment of multiple myeloma]. [PDF]
Lin YX, Jing DH, Mi JQ.
europepmc +1 more source
Risk factors for multiple myeloma and its precursor diseases. [PDF]
Ma W, Zhao L, Zhou W.
europepmc +1 more source
[Prognostic value of the FS-15 frailty score in patients with myelodysplastic syndromes]. [PDF]
Wang X +13 more
europepmc +1 more source
[The role of AKT inhibitors combined with Ruxolitinib in ameliorating myeloproliferative disorders in mice with CALR gene mutations]. [PDF]
Zhang LW +6 more
europepmc +1 more source
[Effect of different induction chemotherapy regimens on autologous hematopoietic stem cell mobilization in patients with multiple myeloma in the new drug era]. [PDF]
Wang XL +8 more
europepmc +1 more source
[Prognostic value of circulating plasma cell in newly diagnosed multiple myeloma treated with bortezomib, lenalidomide, and dexamethasone]. [PDF]
Liu RR +6 more
europepmc +1 more source
[Preventive Regulation of Bone Marrow Mesenchymal Stem Cell Differentiation by α-Zearalenol Ameliorates Bone Loss in Osteoporotic Rats]. [PDF]
He X, Bao M, Tang M, Yao X, Li L.
europepmc +1 more source

